A Miracle Drug for Tuberculosis: Bedaquiline
نویسندگان
چکیده
منابع مشابه
Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient.
5 Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430–1442. 6 Migliori GB, Sotgiu G. Treatment of tuberculosis: have we turned the corner? Lancet 2012; 380: 955–957. 7 De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem...
متن کاملTradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis
BACKGROUND New drugs for the treatment of tuberculosis (TB) are becoming available for the first time in over 40 y. Optimal strategies for introducing these drugs have not yet been established. The objective of this study was to compare different strategies for introducing the new TB drug bedaquiline based on patients' resistance patterns. METHODS AND FINDINGS We created a Markov decision mod...
متن کاملA Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial limitations, in terms of their effectiveness, side-effect profile, and complexity of administration. Bedaquiline is a novel diarylquinoline antibiotic that has recently been investigated as an adjunct to existing therapies for MDR-TB. Currently, limited clinical data are available to evaluate the drug's safety an...
متن کاملBedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
A woman with extremely drug-resistant tuberculosis treated with a drug regimen including linezolid and bedaquiline during her last 3 weeks of pregnancy gave birth to a child without abnormalities. No fetal toxicities were noted by 2 years after delivery. This drug combination might be safe during the late third trimester of pregnancy.
متن کاملFDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.
n engl j med 371;8 nejm.org august 21, 2014 689 regimen is not otherwise available.1 One complexity facing the FDA in reviewing the bedaquiline marketing application was that in one of the phase 2 studies, there were more deaths among patients who had bedaquiline added to a background antimycobacterial drug regimen than among those who had placebo added to the same regimen, despite relatively c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pondicherry Journal of Nursing
سال: 2021
ISSN: 2279-0144
DOI: 10.5005/jp-journals-10084-12174